LOGIN  |  REGISTER
Astria Therapeutics

Nutex Health Provides Update On Its Medical Group In Houston

March 20, 2023 | Last Trade: US$30.28 1.49 -4.69

HOUSTON, March 20, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 19 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today provides an update on Houston Physicians IPA, its independent practice association ("IPA") in Houston.

An IPA is an association of independent physician practices who wish to focus on providing high quality care and to remain independent but need additional resources and expertise to lead the market in value-based care. Houston Physicians IPA offers its providers access to our Clinigence Health cloud-based population health data analytics platform, opportunities to participate in risk-based contracts with payors and the resources of ProCare MSO, Nutex Health's wholly-owned management services organization ("MSO"). 

As of today, Houston Physicians IPA has signed contracts with over 55 primary care physicians and has also signed contracts with multiple specialists in Houston. The physicians have been credentialed and our IPA is in the process of contracting with payors and then beginning patient enrollment later this year.

Nutex Health's integrated healthcare delivery system is comprised of its hospitals, IPAs, our MSO and our cloud-based population health analytics platform. Our inpatient-outpatient model is well aligned operationally and strategically to deliver high-quality and coordinated care to patients in our local communities, while improving the efficiency and overall cost of care. We believe that by taking care of as many of our IPA's enrolled patients at our hospitals, we will not only increase the volumes in our emergency rooms and occupy more of our inpatient beds, but we will also reduce the medical cost ratio ("MCR") in our IPAs, thus making our IPAs more profitable.

"Nutex Health strives to provide outstanding patient care, achieving quality outcomes and in a culture of community engagement across all our hospitals," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

"We are committed to advancing our innovative inpatient-outpatient model, combining the unique strengths of our community-based hospitals, our IPAs comprised of local physicians and our MSO, with our cloud-based data analytics platform tying everything together," stated Warren Hosseinion, M.D., President of Nutex Health.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 19 facilities in 8 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. 

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB